MX2018001816A - Composicion combinada que comprende el compuesto fgf-18. - Google Patents

Composicion combinada que comprende el compuesto fgf-18.

Info

Publication number
MX2018001816A
MX2018001816A MX2018001816A MX2018001816A MX2018001816A MX 2018001816 A MX2018001816 A MX 2018001816A MX 2018001816 A MX2018001816 A MX 2018001816A MX 2018001816 A MX2018001816 A MX 2018001816A MX 2018001816 A MX2018001816 A MX 2018001816A
Authority
MX
Mexico
Prior art keywords
compound
fgf
inhibitor
combination composition
composition
Prior art date
Application number
MX2018001816A
Other languages
English (en)
Inventor
Christoph H Ladel
Guehring Hans
Gigout Anne
brenneis Christian
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2018001816A publication Critical patent/MX2018001816A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con el uso de un compuesto FGF-18 en combinación con un ingrediente activo adicional seleccionado del grupo de un inhibidor de IL-6, un inhibidor del receptor de IL-6, un inhibidor de NGF o un compuesto de toxina botulínica; la composición se puede usar para el tratamiento de un trastorno del cartílago tal como osteoartritis o lesión del cartílago.
MX2018001816A 2015-08-13 2016-08-11 Composicion combinada que comprende el compuesto fgf-18. MX2018001816A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15180859 2015-08-13
PCT/EP2016/069177 WO2017025611A1 (en) 2015-08-13 2016-08-11 Combination composition comprising fgf-18 compound

Publications (1)

Publication Number Publication Date
MX2018001816A true MX2018001816A (es) 2018-05-16

Family

ID=53835964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001816A MX2018001816A (es) 2015-08-13 2016-08-11 Composicion combinada que comprende el compuesto fgf-18.

Country Status (13)

Country Link
US (1) US20180236032A1 (es)
EP (1) EP3334450A1 (es)
JP (1) JP7140677B2 (es)
KR (1) KR20180035911A (es)
CN (1) CN107921095A (es)
AU (1) AU2016306626A1 (es)
BR (1) BR112018002404A2 (es)
CA (1) CA2994638A1 (es)
IL (1) IL257492B (es)
MX (1) MX2018001816A (es)
RU (1) RU2745453C2 (es)
WO (1) WO2017025611A1 (es)
ZA (1) ZA201800974B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005035A2 (pt) * 2017-09-21 2020-09-15 Merck Patent Gmbh proteína de fusão comprendendo porção fgf-18

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1896053B1 (en) * 2004-07-06 2018-10-31 ZymoGenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
RS52710B (en) * 2006-08-25 2013-08-30 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
PL2054050T3 (pl) * 2006-08-25 2013-01-31 Ares Trading Sa Leczenie zaburzeń chrząstki z zastosowaniem FGF-18
SI2187964T1 (sl) * 2007-08-10 2015-01-30 Regeneron Pharmaceuticals, Inc. Visokoafinitetna humana protitelesa proti humanemu živčnemu rastnemu faktorju
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
US10149893B2 (en) * 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis

Also Published As

Publication number Publication date
CA2994638A1 (en) 2017-02-16
BR112018002404A2 (pt) 2018-09-18
IL257492B (en) 2022-06-01
ZA201800974B (en) 2019-04-24
RU2745453C2 (ru) 2021-03-25
IL257492A (en) 2018-04-30
US20180236032A1 (en) 2018-08-23
KR20180035911A (ko) 2018-04-06
RU2018108592A (ru) 2019-09-13
JP2018528186A (ja) 2018-09-27
AU2016306626A1 (en) 2018-02-22
WO2017025611A1 (en) 2017-02-16
EP3334450A1 (en) 2018-06-20
CN107921095A (zh) 2018-04-17
RU2018108592A3 (es) 2020-02-26
JP7140677B2 (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
MX2018005829A (es) Composiciones para tratar el cabello.
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
EA201891251A1 (ru) Бициклические ингибиторы pad4
MY189453A (en) 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2024001617A (es) Composiciones biofarmaceuticas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018015125A (es) Nuevos compuestos antibacterianos.
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MX2017005249A (es) Compuestos para usarse en el tratamiento antihelmintico.
PH12016502001A1 (en) Novel bacteriophage and composition comprising same
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
MX2017001047A (es) Compuestos para usar en el tratamiento antihelmintico.
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
SG11201704766UA (en) Antibacterial composition containing adk protein as active ingredient, or composition for preventing or treating septicemia